{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:52:29Z","timestamp":1783529549570,"version":"3.55.0"},"reference-count":0,"publisher":"African Journals Online (AJOL)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Afr H. Sci."],"abstract":"<jats:p>Background: This systematic review and meta-analysis was conducted to evaluate the safety and effectiveness of Atazanavir\/ritonavir over lopinavir\/ritonavir in human immunodeficiency virus-1 (HIV-1) infection.\r\nMethods: Clinical trials with a head-to-head comparison of atazanavir\/ritonavir and lopinavir\/ritonavir in HIV-1 were included. Electronic databases: PubMed\/Medline CENTRAL, Embase, Scopus, and Web of Science were searched. Viral suppression below 50 copies\/ml at the longest follow-up period was the primary outcome measure. Grade 2-4 treatment-related adverse drug events, lipid profile changes and grade 3-4 bilirubin elevations were used as secondary outcome measures.\r\nResults: A total of nine articles from seven trials with 1938 HIV-1 patients were included in the current study. Atazanavir\/ritonavir has 13% lower overall risk of failure to suppress the virus level &lt; 50 copies\/ml than lopinavir\/ritonavir in fixed effect model (pooled RR: 0.87; CI: 0.78, 0.96; P=0.006). The overall risk of hyperbilirubinemia is very high for atazanavir\/ritonavir than lopinavir\/ritonavir in the random effects model (pooled RR: 45.03; CI: 16.03, 126.47; P&lt; 0.0001).\r\nConclusion: Atazanavir\/ritonavir has a better viral suppression at lower risk of lipid abnormality than lopinavir\/ritonavir. The risk and development of hyperbilirubinemia from atazanavir-based regimens should be taken into consideration both at the time of pre- scribing and patient follow-up.\r\nKeywords: Atazanavir; Atazanavir\/ritonavir; lopinavir\/ritonavir; viral suppression.<\/jats:p>","DOI":"10.4314\/ahs.v20i1.14","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T11:05:22Z","timestamp":1602155122000},"page":"91-101","source":"Crossref","is-referenced-by-count":17,"title":["Atazanavir \/ ritonavir versus Lopinavir \/ ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis"],"prefix":"10.4314","volume":"20","author":[{"given":"Bereket","family":"Molla Tigabu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feleke","family":"Doyore Agide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoo","family":"Mohraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shekoufeh","family":"Nikfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2895","published-online":{"date-parts":[[2020,4,20]]},"container-title":["African Health Sciences"],"original-title":[],"link":[{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/download\/194947\/184135","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/download\/194947\/184135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T11:06:22Z","timestamp":1602155182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/view\/194947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,4,23]]}},"URL":"https:\/\/doi.org\/10.4314\/ahs.v20i1.14","relation":{},"ISSN":["1680-6905"],"issn-type":[{"value":"1680-6905","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,20]]}}}